Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorSaghazadeh, Amene-
Autor(es): dc.creatorRezaei, Nima-
Data de aceite: dc.date.accessioned2026-02-09T11:09:37Z-
Data de disponibilização: dc.date.available2026-02-09T11:09:37Z-
Data de envio: dc.date.issued2020-09-09-
Data de envio: dc.date.issued2020-09-09-
Data de envio: dc.date.issued2020-07-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/42952-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1567576920310298-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1135014-
Descrição: dc.descriptionThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceInternational Immunopharmacology-
Palavras-chave: dc.subjectCOVID-19 - Treatment-
Palavras-chave: dc.subjectImmunoglobulin-
Palavras-chave: dc.subjectTargeted therapy-
Palavras-chave: dc.subjectCorticosteroids-
Palavras-chave: dc.subjectInterleukin 6 (IL-6)-
Título: dc.titleTowards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.